Back to chapter

8.19:

Alternative RNA Splicing

JoVE Core
Molecular Biology
A subscription to JoVE is required to view this content.  Sign in or start your free trial.
JoVE Core Molecular Biology
Alternative RNA Splicing

Languages

Share

RNA splicing is a post-transcriptional mechanism where precursor mRNA, or pre-mRNA, is converted into mature mRNA by removing the introns and re-joining the exons.  Constitutive RNA splicing joins each exon in their order in the gene to produce a single type of mature mRNA. For example, in a eukaryotic gene with five exons, numbered 1 to 5, constitutive splicing of pre-mRNA will result in a mature mRNA with five exons. In contrast, alternative RNA splicing uses a single gene to produce multiple types of proteins by joining or removing different combinations of exons and introns to produce distinct mature mRNAs.  A gene containing five exons might be spliced into a mature mRNA with exons 1 and 5; exons 2, 3 and 5; or exons 1, 3 and 4.  In some cases, the mature mRNA may even contain a retained intron. These variations allow eukaryotic cells to produce a larger assortment of proteins than the number of genes present in their DNA. Alternative mRNA splicing allows the same gene to produce different tissue-specific forms of the mature mRNA. For example, different variants of alpha tropomyosin are expressed in smooth muscle cells, striated muscle cells, and brain cells. Alternative RNA splicing is tightly controlled and is regulated by a set of proteins known as activators and repressors.  Activators bind to specific sequences on the pre-mRNA exons and introns called exonic or intronic splicing enhancers. This binding allows the spliceosome to recognize weak splice sites that are not recognized in constitutive splicing.  In contrast, repressors bind to exonic and intronic splicing silencers.  This prevents the spliceosome from assembling, causing it to skip over specific splice sites. 

8.19:

Alternative RNA Splicing

Alternative RNA splicing is the regulated splicing of exons and introns to produce different mature mRNAs from a single pre-mRNA. Unlike in constitutive splicing where a single gene produces a single type of mRNA, alternative splicing allows an organism to produce multiple proteins from a single gene and plays an important role in protein diversity.

There are five types of alternative RNA splicing that vary in the ways the pre-mRNA segments are removed or retained in the mature mRNA. The first type is exon skipping where some exons, along with all the introns, are selectively removed. This is the most prominent type of alternative splicing observed in humans. The second type, intron retention, occurs when a specific intron is retained in the mature mRNA while the others are removed. This type of splicing is more prevalent in plants than humans. In the third and fourth types of alternative splicing, alternative 5' or 3’ splice sites are selected in specific exons, respectively. This change in 5' and 3' splicing sites shortens or lengthens the exon resulting in different types of mature mRNAs. This type of alternative splicing occurs both in humans and plants. The last and rarest type of alternative RNA splicing is mutually exclusive exons where out of two exons, only one is retained while another one was removed.

Alternative splicing is regulated by different cis-acting elements and trans-acting factors. Cis-acting elements are DNA sequences that are present near structural genes whereas trans-acting factors are other molecules that bind to the DNA. In alternative RNA splicing, the cis-acting elements mainly consist of exon and intron specific splicing enhancers and silencers.  Trans-acting factors, like SR proteins (serine/arginine-rich splicing factors), can bind to the exon or intron splicing enhancers to help the splicing machinery to recognize weak splice sites. On the other hand, proteins like heterogeneous nuclear ribo­nucleoproteins bind to the exon or intron splicing silencers to prevent splicing by masking the splice sites from the spliceosome.

Alternative RNA splicing is common in higher eukaryotes. Almost 95% of human genes are alternatively spliced; therefore, defects in the machinery can significantly impair organ function and can result in cancer and other diseases including neurological and heart disorders. In humans,  mutations that directly affect pre-mRNA splicing account for more than 15% of genetic diseases, such as Hutchinson-Gilford progeria and beta-thalassemia.

Suggested Reading

  1. Chaudhary, Saurabh, Waqas Khokhar, Ibtissam Jabre, Anireddy SN Reddy, Lee J. Byrne, Cornelia M. Wilson, and Naeem H. Syed. "Alternative splicing and protein diversity: Plants versus animals." Frontiers in Plant Science 10 (2019).
  2. Wang, Yan, Jing Liu, B. O. Huang, Yan‑Mei Xu, Jing Li, Lin‑Feng Huang, Jin Lin et al. "Mechanism of alternative splicing and its regulation." Biomedical Reports 3, no. 2 (2015): 152-158.
  3. Singh, Babita, and Eduardo Eyras. "The role of alternative splicing in cancer." Transcription 8, no. 2 (2017): 91-98.